Literature DB >> 21883362

Rapid onset of argyria induced by a silver-containing dietary supplement.

Lynden P Bowden1, Michael C Royer, James R Hallman, Michael Lewin-Smith, George P Lupton.   

Abstract

We describe a 53-year-old man in good general health who presented with an 8-month history of progressive gray hyperpigmentation of the face. He denied using any prescription medications; however, he admitted to taking a herbal supplement. Clinically, the differential diagnosis included hemochromatosis, Wilson's disease and hyperpigmentation secondary to supplement use. Punch biopsies from the left forehead and preauricular region showed heavily sun-damaged skin with a minimal inflammatory infiltrate. Closer inspection, however, revealed minute scattered black/brown particles distributed in the basement membrane zone of eccrine and sebaceous glands. Similar particles were also present in hair follicles, blood vessels and arrector pili muscles. The particles did not stain with Gomori methenamine silver, Fontana-Masson or iron stains. Electron microscopy with energy-dispersive x-ray analysis showed numerous particles, less than 1 µm in greatest dimension, which showed peaks for silver and sulfur. This analytical result confirmed the impression of argyria. Further history revealed that the patient had indeed been taking a silver supplement for several months under the premise that it would boost his immune system. This case is unique in that the patient's hyperpigmentation developed in a short period of time as compared with other reports in the medical literature. Published 2011. This is a US Government work and is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21883362     DOI: 10.1111/j.1600-0560.2011.01755.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  8 in total

1.  Persistence of silver nanoparticles in the rat lung: Influence of dose, size, and chemical composition.

Authors:  Donald S Anderson; Rona M Silva; Danielle Lee; Patricia C Edwards; Arjun Sharmah; Ting Guo; Kent E Pinkerton; Laura S Van Winkle
Journal:  Nanotoxicology       Date:  2014-09-18       Impact factor: 5.913

2.  In vitro biodistribution of silver nanoparticles in isolated perfused porcine skin flaps.

Authors:  Teresa L Leavens; Nancy A Monteiro-Riviere; Alfred O Inman; James D Brooks; Steven J Oldenburg; Jim E Riviere
Journal:  J Appl Toxicol       Date:  2012-07-04       Impact factor: 3.446

3.  Chemical transformations of nanosilver in biological environments.

Authors:  Jingyu Liu; Zhongying Wang; Frances D Liu; Agnes B Kane; Robert H Hurt
Journal:  ACS Nano       Date:  2012-10-17       Impact factor: 15.881

4.  Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model.

Authors:  Ingrid L Bergin; Laura A Wilding; Masako Morishita; Kim Walacavage; Andrew P Ault; Jessica L Axson; Diana I Stark; Sara A Hashway; Sonja S Capracotta; Pascale R Leroueil; Andrew D Maynard; Martin A Philbert
Journal:  Nanotoxicology       Date:  2015-08-24       Impact factor: 5.913

5.  Nanoparticle toxicity by the gastrointestinal route: evidence and knowledge gaps.

Authors:  Ingrid L Bergin; Frank A Witzmann
Journal:  Int J Biomed Nanosci Nanotechnol       Date:  2013

6.  Argyria -- case report.

Authors:  André Lencastre; Maria Lobo; Alexandre João
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

7.  Upper Extremity Friction Burns in the Pediatric Patient: A 10-year Review.

Authors:  Rachel Marchalik; Erin M Rada; Frank P Albino; Tina M Sauerhammer; Michael J Boyajian; Gary F Rogers; Albert K Oh
Journal:  Plast Reconstr Surg Glob Open       Date:  2018-12-04

8.  Argyria after Silver Nitrate Intake: Case Report and Brief Review of Literature.

Authors:  Alma Ileana Molina-Hernandez; Jose Manuel Diaz-Gonzalez; Marcela Saeb-Lima; Judith Dominguez-Cherit
Journal:  Indian J Dermatol       Date:  2015 Sep-Oct       Impact factor: 1.494

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.